

September 29, 2025
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

SymBio Presents Preclinical Results on the Use of Brincidofovir in Malignant Brain Tumors at the Annual Meeting of the Japanese Cancer Association

Tokyo, Japan, September 29, 2025 - SymBio Pharmaceuticals Limited (hereinafter “SymBio” of the “Company”) presented the results of a preclinical efficacy assessment of brincidofovir (BCV) in malignant brain tumors at the 84th Annual Meeting of the Japanese Cancer Association (September 25–27, 2025, Kanazawa, Ishikawa, Japan). The results, previously presented at the American Association for Cancer Research (AACR) in April 2025, were presented at the meeting as an encore abstract.¹

Title: Preclinical Efficacy Assessment of Brincidofovir against Glioblastoma

Presenter: Shoji Nagatani

Presentation No.: P-1249

Conference: The 84th Annual Meeting of the Japanese Cancer Association

Date/Venue: September 25–27, 2025, Kanazawa, Ishikawa, Japan

As announced in our earlier press releases², new results related to this study will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting in November 2025. SymBio will continue to explore the development potential of BCV in the field of malignant brain tumors.

¹ Press release dated May 12, 2025

² Press release dated August 12, 2025

[Contact] Investor Relations Tel: +81(0)3 5472 1125


(Note)

Glioma

Gliomas are brain tumors arising from glial cells. Among them, glioblastoma, the most malignant grade 4 subtype, progresses very rapidly and has a poor prognosis; the median survival after diagnosis is as short as 2 to 18 months, and the 5-year survival rate is 5% or less. Cancers with a 5-year survival rate of 50% or less are classified as “refractory cancers.” Glioblastoma, one such cancer, is estimated to affect approximately 2,000 patients annually in Japan and about 21,000 patients in Europe and the United States. The current standard of care uses temozolomide (brand name: Temodar®) in combination with radiotherapy. The anti-angiogenic drug bevacizumab (brand name: Avastin®) is also used. However, approximately half of patients show resistance to temozolomide, the standard therapy. As no treatment has yet been established to overcome this resistance, there is a strong need for the development of new therapies.

BCV's Business Strategy Based on Three Therapeutic Pillars

Since acquiring the global license to BCV in September 2019, SymBio has been conducting collaborative research with world-class research institutions to unlock BCV's potential in three therapeutic areas. Currently, our management resources and development efforts are centered on three therapeutic pillars: (1) viral infections post-HSCT, (2) hematologic and solid tumors, and (3) neurodegenerative diseases. By expanding our business globally, we aim to maximize the business value of BCV. For the first pillar, we are preparing to initiate a global Phase 3 clinical trial for adenovirus



infection post-HSCT, with a target start date by the end of the year. For the second pillar, in the area of hematologic cancers, we have initiated a Phase 1b/2 clinical trial for NK/T-cell lymphoma, are currently enrolling patients, and aim to submit for regulatory approval in 2028.

Furthermore, within solid tumors, we are considering the initiation of clinical trials for indications such as brain tumors and head and neck cancer. In the field of neurodegenerative diseases, we plan to advance clinical trials targeting multiple

sclerosis (MS) and progressive multifocal leukoencephalopathy (PML) in the future.